Register Login

JUPITER NEUROSCIENCES, INC. (JUNS)

SymbolJUNS
NameJUPITER NEUROSCIENCES, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address1001 NORTH US HWY 1,SUITE 504, JUPITER, Florida, 33477, United States
Telephone(561) 406-6154
Fax—
Email—
Websitehttps://www.jupiterneurosciences.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001679628
Description

Jupiter Neurosciences is a clinical stage research and development pharmaceutical company. The Company has developed a unique resveratrol platform product targeting treatment of neuro-inflammation. The product, called JOTROL , has many potential indications of use for rare diseases, which of we primarily are targeting Mucopolysaccharidoses Type 1, Friedreichs Ataxia, and MELAS as well as ALS which is in an early development stage. In the larger disease areas, we are primarily targeting Mild Cognitive Impairment/early Alzheimers disease with TBI/concussions and Covid-19 in early development stages. Based on available scientific literature, we believe that JOTROL is the first and only resveratrol product in the world that delivers a therapeutically effective dose of resveratrol in the blood stream without causing gastrointestinal side effects.

Additional info from NASDAQ:
Jupiter Neurosciences is a clinical stage research and development pharmaceutical company. The Company has developed a unique resveratrol platform product targeting treatment of neuro-inflammation. The product, called JOTROL , has many potential indications of use for rare diseases, which of we primarily are targeting Mucopolysaccharidoses Type 1, Friedreichs Ataxia, and MELAS as well as ALS which is in an early development stage. In the larger disease areas, we are primarily targeting Mild Cognitive Impairment/early Alzheimers disease with TBI/concussions and Covid-19 in early development stages. Based on available scientific literature, we believe that JOTROL is the first and only resveratrol product in the world that delivers a therapeutically effective dose of resveratrol in the blood stream without causing gastrointestinal side effects.

2026-06-26 17:34

New Form S-1 - JUPITER NEUROSCIENCES, INC. <b>Filed:</b> 2026-06-26 <b>AccNo:</b> 0001493152-26-030312 <b>Size:</b> 933 KB

Read more
2026-06-22 11:30

(99% Neutral) JUPITER NEUROSCIENCES, INC. (JUNS) Announces New Board Appointment

Read more
2026-06-22 08:36

New Form ARS - JUPITER NEUROSCIENCES, INC. <b>Filed:</b> 2026-06-22 <b>AccNo:</b> 0001493152-26-029492 <b>Size:</b> 2 MB

Read more
2026-06-22 08:34

New Form DEF 14A - JUPITER NEUROSCIENCES, INC. <b>Filed:</b> 2026-06-22 <b>AccNo:</b> 0001493152-26-029491 <b>Size:</b> 5 MB

Read more
2026-06-22 08:32

New Form 424B3 - JUPITER NEUROSCIENCES, INC. <b>Filed:</b> 2026-06-22 <b>AccNo:</b> 0001493152-26-029490 <b>Size:</b> 36 KB

Read more
2026-06-09 17:01

New Form PRE 14A - JUPITER NEUROSCIENCES, INC. <b>Filed:</b> 2026-06-09 <b>AccNo:</b> 0001493152-26-027920 <b>Size:</b> 5 MB

Read more
2026-06-05 20:30

(99% Neutral) JUPITER NEUROSCIENCES, INC. (JUNS) Announces New Board Appointment

Read more
2026-06-05 17:32

New Form 424B3 - JUPITER NEUROSCIENCES, INC. <b>Filed:</b> 2026-06-05 <b>AccNo:</b> 0001493152-26-027503 <b>Size:</b> 74 KB

Read more
2026-06-05 12:23

Director Brady Allison W 🟢 acquired 100.0K shares (1 derivative) of JUPITER NEUROSCIENCES, INC. (JUNS) at $0.28 Transaction Date: Jun 02, 2026 | Filing ID: 027421

Read more
2026-06-05 01:01

Elmasri Saleem 🟢 acquired 525.6K shares (1 derivative) of JUPITER NEUROSCIENCES, INC. (JUNS) at $0.28 Transaction Date: Jun 02, 2026 | Filing ID: 027366

Read more